Metformin may be beneficial for those over 60, but younger individuals might explore lifestyle changes while awaiting the results of the TAME trial. The discussion highlights a shift in longevity research, emphasizing the use of biological clocks to measure age and health indicators, providing a more immediate feedback loop for evaluating the effects of treatments like metformin.
